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Abstract A disease registry uses observational study
methods to collect defined data on patients with a particular
condition for a predetermined purpose. By providing compre-
hensive standardised data on patients with kidney disease,
renal registries aim to provide a ‘real world’ representation
of practice patterns, treatment and patient outcomes that may
not be captured accurately by other methods, including
randomised controlled trials. Additionally, using registries to
measure variations in outcomes and audit care against stan-
dards is crucial to understanding how to improve quality of
care for patients in an efficacious and cost-effective manner.
Registries also have the potential to be a powerful scientific
tool that can monitor and support the translational process
between research and routine clinical practice, although their
limitations must be borne in mind. In this review, we describe
the role of the UK Renal Registry as a tool to support transla-
tional research. We describe its involvement across each stage
of the translational pathway: from hypothesis generation,
study design and data collection, to reporting of long-term
outcomes and quality improvement initiatives. Furthermore
we explore how this role may bring about improvements in
care for adults and children with kidney disease.
Keywords Registry . Kidney disease . Translational
research . Standards
Introduction
A disease registry is an organised system that uses observa-
tional study methods to capture defined data on patients with a
particular condition for a predetermined purpose [1].
Registries provide a comprehensive ‘real world’ representa-
tion of practice patterns, treatment and patient outcomes that
may not be accurately captured by other methods, including
randomised controlled trials (RCTs) [2]. The oldest disease-
specific registry dates from 1856, and recent literature esti-
mates that there are over 200 such registries in the UK alone
[3].
Registries have the potential to help improve patient care
by supporting the translation of research into clinical practice.
By collecting longitudinal data, registries provide epidemio-
logical information regarding the natural history and burden of
disease for the population examined, which may help to in-
form research and the development of clinical trials. From a
public health perspective, registries can monitor trends in dis-
ease and treatment outcomes, and they have the ability to
assess the impact of new interventions, as well as audit attain-
ment of National guidance [4]. This is particularly relevant for
paediatric chronic kidney disease (CKD), where a small pop-
ulation of patients require complex and costly treatments, and
in whom certain outcomesmay not be evident for long periods
of time.
Many renal registries exist globally that focus on patients
with end-stage renal disease (ESRD) requiring renal replace-
ment therapy (RRT; dialysis or renal transplantation). A recent
systematic review identified 48 such registries around the
world, although more have since been established [5].
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Others, however, focus on disease subgroups (e.g. The
PodoNet Consortium for patients with steroid-resistant ne-
phrotic syndrome, www.podonet.org) or specific treatments
(e.g. the International Paediatric Dialysis Network, www.
pedpd.org). The UK Renal Registry (UKRR) was founded
in 1995 to improve equity of access to and quality of care
for patients receiving treatment for ESRD. Since its inception,
it has adapted to changing healthcare, governance, research
and technological requirements to become a pioneering regis-
try with regards to centre-specific reports, health services re-
search, quality improvement initiatives and more recently, ac-
cess to near real-time patient data [6]. In this review, we seek
to outline and describe the structure and roles of the UKRR
with case examples and to highlight ways in which these con-
tribute to improving care standards across a translational re-
search spectrum.
Translational research
Increasingly, there is frustration at the delays in effective trans-
lation of research findings into practice: Bthat knowledge and
new treatments reach patients for whom theywere intended and
are implemented appropriately^ [7, 8]. It has been recommend-
ed that investment in this area will create an efficient and cost-
effective research process whilst driving improvements in
health policy [9, 10]. This is particularly vital for the field of
nephrology, where a significant proportion of healthcare expen-
diture is spent on a relatively small number of patients [11].
Two key translational gaps have been identified: (1) the
transition of ideas from basic and clinical research into the
development of new products and approaches to treatment
and (2) the implementation of these products or approaches
into clinical practice [12]. This second translational gap has
been deemed a priority in the field of nephrology [13]. From
identifying causal associations to supporting trial design and
analysis, the UKRR and translational epidemiology play a
crucial role in this research process and in knowledge synthe-
sis [14, 15] (Fig. 1).
UKRR development and structure
Before the UKRR, manually collected data was gathered by
the European Renal Association and European Dialysis and
Transplant Association (ERA-EDTA; previously named the
EDTA Registry), for England, Wales, Scotland and Northern
Ireland. In 1991 the Scottish Renal Registry (SRR) was
established [16], followed by the UKRR in 1995. From the
outset, the aim of the UKRR was to provide a resource to
monitor UK patient care and to improve equity of access to
RRT. Its approach was to establish a database with the capa-
bility to extract data electronically from health records in each
renal unit. This was followed, in 1997, by the development of
a British Association For Paediatric Nephrology (BAPN) pae-
diatric registry database which later amalgamated with the
UKRR in 2009. Data from the paediatric renal units in
Scotland comes direct to the BAPN database at the UKRR.
Currently, work is ongoing to fully integrate paediatric data
into the main UKRR database so that the care of patients can
be followed seamlessly from childhood to adulthood.
Today, the UKRR is a readily accessible source of patient-
level data for researchers, clinicians, health commissioners
and the public. It extracts, analyses and reports data from 71
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adult and 13 paediatric renal centres, with cleaned, validated
data from the 11 Scottish adult renal units coming via the
SRR. It can link to external databases, including Hospital
Episode Statistics (HES; for hospital admissions), the Office
of National Statistics (ONS; for mortality) and Public Health
England (for reportable infections, like methicillin-resistant/
methicillin-sensitive Staphylococcus aureus, Clostridium
difficile and Escherichia coli bacteraemia), thus substantially
enhancing its use in audit and research. Data collection is now
extending beyond RRT however. Following pilot work [17],
data collection has begun for acute dialysis and plasma ex-
change in acute kidney injury, an area not covered by many
other renal registries. Since January 2016, data capture also
includes patients with an estimated glomerular filtration rate
(eGFR) of <30 ml/min/1.73m2. These data will enable a novel
comprehensive assessment of the pre-dialysis cohort, includ-
ing preparation for dialysis and quality of care for people with
ESRD who choose not to start RRT.
Roles of the UKRR across the translational research
spectrum
Providing evidence of the need for research
The collection and interpretation of longitudinal data by renal
registries enable users to understand trends in disease inci-
dence or prevalence among different patient populations
[18]. By gathering data that is centre- and region-specific,
the UKRR is able to highlight disparities in renal outcomes
across the UK that require further investigation and health
service investment.
Registries can identify novel associations or gaps in knowl-
edge that may lead to the generation of hypotheses and, where
appropriate, the subsequent development of funding applica-
tions for primary research to explore these in detail and devel-
op interventions. An example of this role is the recently
awarded National Institute of Health Research (NIHR) fellow-
ship: ‘Why do children with chronic kidney disease present
late to specialist services?’ (NIHR DRF 2016–09-055). This
study, designed to examine whether modifiable factors exist
for children who present to specialists within a 90-day win-
dow from commencing RRT, was developed following a
UKRR report describing the cross-sectional burden among
the UK paediatric cohort [19].
Registries have historically focused on process measures
(e.g. treatment modality, treatment duration/ frequency) and
routine clinical outcomes (e.g. anaemia and bone mineral me-
tabolism), with little or no data covering the life outcomes that
are important to paediatric patients and their families, such as
educational attainment, future prospects and psychological
health. To address this, primary research can be embedded
within the UKRR to identify key psycho-social variables
which could be incorporated into routine data collection.
The Surveying People Experiencing young Adult Kidney fail-
ure (SPEAK) study [20] sets out to achieve this. By collecting
socio-demographic, psychological health and lifestyle data
and linking these to UKRR data, SPEAK seeks to understand
whether certain clinical variables, including age of disease
onset, are associated with poorer quality of life outcomes in
young adults. It is expected that the SPEAK study will be
powered to identify ‘at risk’ populations that may benefit from
targeted interventions.
Designing studies and data collection
While RCTs have previously been assigned the highest grad-
ing of evidence [21], they are often expensive, time-
consuming and, due to strict inclusion criteria, have limited
external validity (generalizability) to wider patient popula-
tions. In addition, for rare subgroups of paediatric kidney dis-
ease, small numbers and long follow-up periods often pre-
clude their use. Observational data gathered from renal regis-
tries can provide an effective alternative for monitoring patient
disease patterns and trends. They can also be used to compare
treatment efficacy, although internal validity is limited due to
the lack of randomization [22]. Registries may guide develop-
ment of methodology in observational studies, for example by
providing data on the frequency of exposure for any future
case–control or cohort studies (where exposure is measured),
aiding the calculation of study power.
Where feasible, registries can support RCT development
by identifying suitable patients for recruitment and by moni-
toring long-term outcomes for the studied population. More
recently, high-quality registries have been used as the platform
from which to recruit, randomise and follow up patients, lead-
ing to the emergence of the so-called ‘registry-based RCT’.
Compared with conventional RCTs, registry-based RCTs are
low in cost and have generally less stringent eligibility criteria,
which, together with potential high levels of patient follow-up,
may enhance generalizability and provide a more realistic de-
piction of the impact of treatment [23, 24].
The UKRR has recently been working with the Cambridge
Clinical Trials unit to contribute to its first registry-based RCT
examining whether ergocalciferol reduces all-cause mortality
in adult dialysis patients [25]. The participants will be follow-
ed up remotely using registry data and linkage to other clinical
datasets, including HES. What is unique to this registry-based
trial is that serum calcium levels are being fed back to the
clinical trials unit in near real-time, thereby providing an ef-
fective feedback mechanism for safety monitoring.
Monitoring practice–audit and benchmarking
Registries can monitor whether best practice is implemented
and clinicians are adhering to updated, evidence-based
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national guidelines. The UKRR audits data against national
standards and ensures that centres are achieving a minimum
standard of patient care, with this information made open to
scrutiny from patients and the public in annual reports.
Examples of this in paediatrics include adherence to
National standards set by the National Institute for Clinical
Excellence (NICE) and BAPN for anaemia and transplant-
recipient blood pressure management, respectively [26, 27].
Data presented by centre must be cautiously interpreted, how-
ever, with adjustment for differences in case mix before any
conclusion can be drawn on the possible existence of Bcentre
effects^ [28]. Centre-level comparisons, both against each
other and with national guidelines, allow high-performing
centres to be identified and provide insight into unmeasured
structural and organisational processes that may subsequently
drive quality improvement initiatives in other units.
Delivering quality improvement
Quality improvement (QI) can be defined as the combined and
unceasing efforts of everyone—kidney healthcare profes-
sionals, patients with kidney disease and their families, com-
missioners of kidney services, researchers, and educators—to
make changes that will lead to better patient outcomes, better
system performance and better professional development [29].
By continuously collecting and comparing outcome data
from renal units, renal registries are well placed to underpin
quality improvement work. In conjunction with the Health
Foundation and Kidney Research UK, the ASSIST-CKD (A
programme to Spread eGFR graph Surveillance for the early
Identification, Support and Treatment of people with CKD)
study is an example of UKRR data being used to provide
outcomes and analysis for QI. With the overarching aim of
reducing late presentation in the adult CKD population,
ASSIST-CKD uses a novel software package embedded in
hospital laboratories to generate eGFR graphs from patient
results over time, alerting primary care teams of deterioration
that may not have been otherwise identified [30]. Routine data
collection of incident ESRD patients (including late presenta-
tion) is serving as the outcome measure.
Collaboration is key to successfully raising care standards
across the country. This is demonstrated by the recently
established Kidney Quality Improvement Partnership
(KQuIP) initiative (www.thinkkidneys.nhs.uk/kquip). This
network of professionals and patients is committed to
developing, supporting and sharing quality improvement
initiatives with the purpose of improving the care and
quality of life for people of all ages with kidney disease. The
network aims to do this by embedding quality improvement
programmes into clinical practice, by understanding and
reducing variation in care and by sharing good practice
among renal units.
International comparisons and collaborations
Data from renal registries can be used to compare patient
outcomes at the international level, and the UKRR provides
anonymized data to the ERA-EDTA Registry [31] as well as
aggregate data to the US Renal Data System (USRDS) [32].
Such global collaborations enable clinicians and researchers to
study rare disease outcomes in larger populations and to iden-
tify variations in outcomes that may occur due to differing
practice patterns between countries. Collaborative initiatives
such as the European Reference Network (ERN) for kidney
disease will also help optimise the development and imple-
mentation of innovative treatments, whilst providing a focal
point within the European community for training, research
and information sharing [33].
Efficient sharing of information among countries, however,
requires collaboration between renal registries to standardise
data items and data sets. A good example of this is the ERA-
EDTA Registry’s ‘QUality European STudies’ (QUEST) ini-
tiative, which has supported the development of standardised
datasets and increased availability of data on clinical perfor-
mance indicators alongside increased access to automated da-
ta collection [34].
UKRR activities beyond audit and research
PatientView
PatientView (PV) is a web-based system that provides patients
and clinicians with rapid access to local laboratory results,
which are uploaded daily (Fig. 2). In addition, patients can
view information regarding their diagnosis and treatment; read
clinic letters; enter personal data (such as blood pressure or
weight) from their own records. It was established in 2004 by
the Renal Information Exchange Group (RIXG) and is now
available in 90% of UK nephrology centres, funded by con-
tributions from renal centres in England, Wales and Northern
Ireland and by the Government of Scotland. Patient users re-
port satisfaction with the tool and perceive it to be helpful in
managing their condition [35]. Furthermore, its ability to con-
temporaneously collect data linked to the UKRR and National
Registry of Rare Kidney Diseases (RaDaR) is crucial to
supporting rare disease research and the development of novel
registry-based trials in the UK.
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The National Registry of Rare Kidney Diseases
Informative clinical data is a necessary step to improving the
treatment and outcomes of patients with rare diseases.
Embedded in the UKRR framework lies the National Registry
of Rare Kidney Diseases, which was established in 2011 at the
request of the Renal Association and BAPN following UK and
EU recommendations to improve access to high-quality care for
patients with rare diseases [36, 37].
In partnership with patients, RaDaR aims to facilitate re-
search and improve the care of patients with rare kidney dis-
eases. It is a comprehensive clinical database that captures both
generic and disease-specific information on patients from a
growing list of diseases (www.rarerenal.org), the most recent
being fibromuscular dysplasia and Fabry disease [38]. This
database was developed by rare disease experts and patients
to develop care standards and research opportunities. Careful
characterisation of well-defined patients has supported the de-
velopment of National Studies into rare disease subgroups (e.g.
the National Study of Nephrotic Syndrome, NephroS study) as
well as the reporting of novel genotype–phenotype correlations
[39, 40]. Long-term surveillance will enable outcomes into
adulthood to be described. Grant applications are also more
likely to succeed when accurate estimates of patient cohorts
are known and patients have already consented to being
approached directly about research opportunities. Work is also
underway to develop an international version of RaDaR, which
will serve to further increase our knowledge of rare renal dis-
ease. Recruitment targets set for the NIHR have been amended
upward from 10,000 to 25,000, reflecting the success of the rare
disease initiative.
In conjunction with PV, RaDaR empowers patients to enter
personal information, including patient-reported quality of life
and outcome measures, into their clinical records. By operat-
ing within the UKRR, PV and RaDaR benefit from the
existing governance infrastructure for automated data collec-
tion, as well as its technical expertise. Ongoing research into
rare renal disease also supports evolution of the UKRR dataset
Fig. 2 PatientView example
screens (adult test
patient). Reproduced with
permission from the UK Renal
Registry
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as our understanding of disease determinants improves.
Future developments, including a national kidney biobank,
may be supported by the RaDaR platform, enabling linkage
of patient’s clinical information with biological data. Together
with the UKRR, PVand RaDaR offer a sustainable resource of
longitudinal information on rare diseases that may help drive
forward improvements in care pathways, access to services
and research into better treatments.
Limitations of registries and the UKRR
Limitations to registries exist and must be considered when
using data. Registries can be expensive and time-consuming
to establish and maintain. They are also only as accurate as the
data entered at each renal unit and so rely on front-line clini-
cians to ensure data returns are correct and complete. For
example, in the UK, data completeness for comorbidity at
the start of RRT remains at an undesirable level (29/62 of
UK adult centres have <75% data completeness). This state
of affairs limits the UKRR’s ability to directly adjust for case
mix [6], which may be particularly problematic when the
presence of comorbidity may be clinically relevant to ESRD
outcomes [41, 42]. Missing data may introduce bias, and im-
putation methods cannot fully overcome this problem.
Linkage to other routine databases has been successfully used
in large observational studies to address this problem [43] and
is being explored within the UKRR framework. For the pae-
diatric dataset, relatively small numbers of patients can restrict
the statistical power achievable in observational studies, but
this can be improved by sharing data with other countries
through, for example, the European Society for Paediatric
Nephrology (ESPN) ERA-EDTA Registry. Furthermore, ob-
servational studies generated using registry data are generally
hypothesis generating and can only rarely demonstrate causal-
ity (e.g. assessing a natural experiment) [4]. Despite the use of
statistical methods to adjust for observed confounders, there is
always the possibility that unmeasured confounders may have
generated false associations. Finally, laboratory parameters
obtained from renal centres may demonstrate a high degree
of variability for a given test, although this effect is likely to be
small [42].
Future directions
To continue supporting improvements in the care of people
with kidney disease, registries must have the capacity to
evolve—both in terms of their technological infrastructure as
well as their involvement in translational health research and
development of health policy. Recognising this, the UK Renal
Data Collaboration (UKRDC) was established in 2013. The
UKRDC seeks to enable data from electronic health records to
be standardised for the purposes of all member organisations
(Fig. 3), supporting the move towards paperless records and
‘streamlining’ data use to improve efficiency for renal units. It
will provide a more dynamic platform from which datasets
can be added to or amended, allowing data collection to
evolve as our knowledge of renal disease advances [44]. It
has already supported the running of an RCT, SIMPLIFIED
(discussed above), with contemporaneous feedback for certain
adverse events monitoring and has the potential to support the
collection of patient-reported outcome measures via PV in
national data collection.
The aim of the recent UK Renal Research Strategy (2016)
is to support the improvement of renal care through research
[13]. Developed with professional and patient bodies, its rec-
ommendations include increased engagement of professionals
and public with research; capitalisation of the full spectrum of
research opportunities for maximum benefit to patient care;
establishment of a multi-disciplinary and collaborative ap-
proach to research; and supporting the training of future re-
searchers. We believe that the UKRR can play an important
role in bringing each of these aims to fruition in a sustainable
and cost-effective manner.
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